Literature DB >> 9815443

Malaria Chemoprophylaxis in German Tourists: A Prospective Study on Compliance and Adverse Reactions.

.   

Abstract

Background: The number of tourists visiting malaria endemic regions is continuously increasing. The risk of aquiring malaria infection can largely be prevented by the regular use of chemoprophylactic drugs combined with using protective measures against mosquito bites. In a prospective study we wished to determine the tolerability of chemoprophylactic drugs and the factors that influence compliance with malaria chemoprophylaxis and antimosquito measures. Method: German travelers (n = 6504) who attended the Berlin Institute of Tropical Medicine in Berlin for pretravel medical advice were interviewed by phone 4 weeks after their journeys about compliance with the recommended malaria chemoprophylaxis and the incidence of side effects.
Results: Compliance was better with mefloquine (94.5%) than with chloroquine (85.9%) (p<.001) or chloroquine plus proguanil (79.8%) (p<.001). Compliance was influenced by the purpose of travel, duration of stay, places of stay, and adverse reactions. Side effects occurred in 20.6% of the travelers who took chemoprophylactic drugs. There was no significant difference in the incidence of side effects between the three drug regimens, but people who took mefloquine more often reported neuropsychiatric reactions (6.5% versus 3.9% with chloroquine and 3.6% with chloroquine and proguanil; p<.001)). Side effects were usually mild to moderate and in no instance required hospitalization. People who took their drugs with meals less often reported side effects (15.2%) (p<.01).
Conclusion: The knowledge of user profiles (and particular factors that presage side effects and noncompliance) may help us to improve pretravel counseling, thereby reducing the risk that travelers may acquire malaria infection.

Entities:  

Year:  1996        PMID: 9815443     DOI: 10.1111/j.1708-8305.1996.tb00729.x

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  10 in total

Review 1.  Malaria: prevention in travellers.

Authors:  Ashley M Croft
Journal:  BMJ Clin Evid       Date:  2007-11-29

Review 2.  Extracts from "Clinical Evidence". Malaria: prevention in travellers.

Authors:  A Croft
Journal:  BMJ       Date:  2000-07-15

3.  [Painless jaundice after holidays in Tanzania].

Authors:  R R Plentz; H Lenzen; M P Manns; J S Bleck
Journal:  Internist (Berl)       Date:  2005-10       Impact factor: 0.743

Review 4.  A week in the life of a travel clinic.

Authors:  D C Blair
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

5.  The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials.

Authors:  Christoph R Meier; Karen Wilcock; Susan S Jick
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 6.  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers.

Authors:  A M J Croft; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

7.  Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?

Authors:  Ashley M Croft; Andrew Herxheimer
Journal:  BMC Public Health       Date:  2002-03-25       Impact factor: 3.295

8.  Recommendations for malaria prevention in moderate to low risk areas: travellers' choice and risk perception.

Authors:  Rachel Voumard; Delphine Berthod; Clotilde Rambaud-Althaus; Valérie D'Acremont; Blaise Genton
Journal:  Malar J       Date:  2015-04-01       Impact factor: 2.979

9.  Chloroquine (antimalaria medication with anti SARS-CoV activity) solubility in supercritical carbon dioxide.

Authors:  Mahboubeh Pishnamazi; Saber Hosseini; Samyar Zabihi; Fatemeh Borousan; Ali Zeinolabedini Hezave; Azam Marjani; Saeed Shirazian
Journal:  J Mol Liq       Date:  2020-10-13       Impact factor: 6.165

10.  Adherence to chemoprophylaxis and Plasmodium falciparum anti-circumsporozoite seroconversion in a prospective cohort study of Dutch short-term travelers.

Authors:  Sanne-Meike Belderok; Anneke van den Hoek; Will Roeffen; Robert Sauerwein; Gerard J B Sonder
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.